Journal article
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
American journal of hematology, Vol.98(2), pp.300-308
02/2023
DOI: 10.1002/ajh.26784
PMCID: PMC10107934
PMID: 36588409
Abstract
Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high relapse rates and a poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, a specific review of limited stage (LS) PBL patients is not available to evaluate outcomes and justify treatment recommendations. We performed a retrospective review of LS PBL cases to provide insight into this rare disease. Our cohort consisted of 80 stage I or II PBL patients from 13 US academic centers. With a median follow up of 34 months (1-196), the 3-year progression-free survival (PFS) and overall survival (OS) of the entire cohort were 72% (95% CI 62, 83) and 79% (95% CI 70, 89), respectively. The 3-year PFS and OS of patients treated with frontline chemotherapy alone was 65% (95% CI 50, 84) and 71% (95% CI 56, 89), respectively, compared to 85% (95% CI 72, 100) and 96% (95% CI 89, 100), respectively, in patients treated with combined frontline chemotherapy with radiation consolidation. Our data demonstrate favorable outcomes in LS PBL with no improvements in outcome from aggressive frontline treatment including Hyper-CVAD or auto-SCT consolidation. Multivariate regression analysis (MRA) demonstrated improved PFS for patients receiving EPOCH based frontline therapy versus CHOP (HR: 0.23; p = 0.029). Frontline chemotherapy followed by radiation consolidation versus chemotherapy alone appeared to be associated with improved relapse and survival outcomes but did not show statistical significance in MRA.
Details
- Title: Subtitle
- Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
- Creators
- Brian T Hess - MUSC Hollings Cancer CenterAnshu Giri - Fox Chase Cancer CenterYeonhee Park - MUSC Hollings Cancer CenterKrina K Patel - The University of Texas MD Anderson Cancer CenterBrian K Link - University of IowaGrzegorz S Nowakowski - Mayo ClinicSeth M Maliske - Sanford HealthSonia Fortin - Mayo Clinic, Rochester, Minnesota, USA.Julio C Chavez - Moffitt Cancer CenterHayder Saeed - Moffitt Cancer CenterBrian T Hill - Cleveland ClinicAlex V Mejia Garcia - Cleveland ClinicKami J Maddocks - The Ohio State UniversityWalter Hanel - The Ohio State UniversityNina D Wagner-Johnston - Sidney Kimmel Comprehensive Cancer CenterMarcus R Messmer - Fox Chase Cancer CenterBrad S Kahl - Washington University in St. LouisMarcus Watkins - Washington University in St. LouisJuan Pablo Alderuccio - Sylvester Comprehensive Cancer CenterIzidore S Lossos - Sylvester Comprehensive Cancer CenterSunita Nathan - Rush University Medical CenterVictor M Orellana-Noia - Emory UniversityCraig A Portell - University of VirginiaDaniel J Landsburg - University of PennsylvaniaEmily C Ayers - University of VirginiaJorge J Castillo - Dana-Farber Cancer Institute
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.98(2), pp.300-308
- DOI
- 10.1002/ajh.26784
- PMID
- 36588409
- PMCID
- PMC10107934
- NLM abbreviation
- Am J Hematol
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Language
- English
- Date published
- 02/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359851402771
Metrics
21 Record Views